ProfileGDS5678 / 1425706_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 54% 55% 66% 58% 66% 65% 68% 67% 63% 67% 60% 63% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8947664
GSM967853U87-EV human glioblastoma xenograft - Control 23.3299554
GSM967854U87-EV human glioblastoma xenograft - Control 33.3816355
GSM967855U87-EV human glioblastoma xenograft - Control 43.9637366
GSM967856U87-EV human glioblastoma xenograft - Control 53.4469958
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0049866
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9557465
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1327468
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0905267
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7661463
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0263867
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5861460
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7744263
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6356961